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OBJECTIVES: To evaluate the relative costs and beneﬁ ts, from a payer perspective,
between live attenuated inﬂ uenza vaccine, trivalent (LAIV) and trivalent inactivated 
inﬂ uenza vaccine (TIV) for eligible children 24–59 months of age. METHODS: We 
conducted a payer perspective, cost consequence analysis of LAIV compared to TIV, 
using patient-level data from a head-to-head randomized control trial (RCT) supple-
mented with cost data from published literature and health claims analysis. Model
outcomes included total direct costs to payers and cases of inﬂ uenza avoided for a
single inﬂ uenza season. Vaccine related costs included average payer reimbursement
for vaccine, administration costs, and related adverse events. Cost related to break-
through cases of inﬂ uenza were also considered. Vaccine dosage and percentage of 
vaccine naïve children receiving two doses (69.4%) were assumed to mirror the RCT. 
All costs were reported in 2008 US dollars. Sensitivity analyses (SA) were run.
RESULTS: Due in part to the higher estimated efﬁ cacy among young children (54%
fewer inﬂ uenza cases), LAIV had lower total direct costs per child ($83.75) compared
to TIV ($92.00). Based on this model, use of LAIV is estimated to result in a cost 
savings of $8.26 per vaccinated child (95% CI:$3.09-$13.39 savings). For every
100,000 children vaccinated, there were an estimated 5,572 fewer cases of inﬂ uenza 
among children receiving LAIV. Despite LAIV’s higher per dose cost ($23.81 vs $14.14
per dose), LAIV lowered overall health care utilization and resulted in a net cost
savings. The SA found that difference in vaccine acquisition and administration prices, 
difference in vaccine efﬁ cacy, the proportion of children receiving two doses, and costs 
of hospitalization for inﬂ uenza were inﬂ uential parameters in the model. CONCLU-
SIONS: The payer speciﬁ c analysis shows that compared to vaccinating with TIV,
LAIV may lower costs and help reduce inﬂ uenza cases in eligible children aged 24 to 
59 months.
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INFLUENZA: THE DEMOGRAPHICS AND TIME SPENT IN HOSPITALS
OF THOSE INFECTED
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OBJECTIVES: Yearly, people all around the country get ﬂ u shots to help prevent the
ﬂ u virus, but still a large number of Americans are diagnosed with the ﬂ u each year.
What we will examine in this study are the demographics of pediatric patients infected 
with this virus so that we can ﬁ nd some of the contributing factors requiring inpatient 
treatment for the ﬂ u. METHODS: We use data from the 2005 National Inpatient
Sample provided by the Healthcare Cost & Utilization Project. We will look at age, 
race and gender as well as the amount of time pediatric patients spend in the hospital 
and the total charges incurred while hospitalized. Also, we will look at the diagnoses
and procedures performed while in the hospital. We have 2578 patients with the ﬂ u 
and 2600 patients not diagnosed with the ﬂ u. Statistical methods were performed using
the statistical software, SAS, including frequency counts, pie and bar graphs, kernel 
density and logistic and linear regressions. RESULTS: We will see that for the large
percentage of people going into the hospital for the ﬂ u, most are only there for 3 days 
(85%); they are Caucasian (55%), incur $16,500 (average) in charges while hospital-
ized, are between 0 and 3 years old (51%), male (55%), and have a low risk factor of 
death according to the Charlson index. The study will yield a better understanding of 
the demographics and length of stay of ﬂ u patients. CONCLUSIONS: What we also 
see is that patients with certain previous diagnosed diseases and procedures performed 
have a higher total cost and longer length of stay. The main diagnosis was lung disease
and patients with this disease had signiﬁ cantly higher total charges as did patients with 
an endotracheal tube, spinal tap, or packed cells procedure performed.
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OBJECTIVES: Gram-negative bacteria strains result in costly, and in some cases 
deadly, pneumonia related hospitalizations. Little information exists on acute hospital 
care and associated costs of gram negative pneumonia at a national level. Our objec-
tives were to assess the prevalence of hospital stays for gram negative pneumonia,
demographically and clinically characterize patients, assess hospital care patients 
received, identify associated costs, and quantify the clinical and economic burden of 
gram negative pneumonia in the United States. METHODS: Using the 2005 HCUP
database, sponsored by the Agency for Healthcare Research and Quality, we assessed 
relevant patient principal and secondary diagnoses, primary and secondary proce-
dures, demographics, and hospital charges, as well as payer composition. An event-
based approach was used to assess resource use and costs associated with all gram 
negative bacteria. Charges were adjusted to 2008 US dollars. RESULTS: In 2005, 
11,032 and 14,354 patients were admitted with principal and secondary diagnoses, 
respectively, of pneumonia due to gram-negative bacteria infection. Total annual per
capita charges associated with these hospital stays were $37,010 per admission as
principal diagnosis and $132,066 per admission as secondary diagnosis. This resulted
in $328 million and $1.17 billion nationally per principal and secondary diagnoses
admissions respectively. For all patients, the inpatient mortality rate was 13%, with
nearly 60% of patients requiring additional care after their discharge. The most 
common procedures for all patients included ventilation (32%) and tracheotomies 
(11%). Pseudomonas was the most frequent and the most expensive gram negative 
strain, accounting for 53% of the total hospital stays for principal diagnosis patients 
and 43% for secondary diagnosis patients. CONCLUSIONS: These results present 
the substantial hospital-speciﬁ c burden of pneumonia due to gram-negative bacteria, 
and highlight the need to explore opportunities to decrease the infection rate and/or 
reduce their potency once infection occurs.
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OBJECTIVES: To conduct a systematic literature review of studies in peer-reviewed 
journals on the epidemiology and economics of invasive meningococcal disease from 
1997–2007. METHODS: This review employed standard methodology to extract 
studies from the Scopus on-line database of peer-reviewed, medical and public health
literature from the preceding 10 years. U.S. and international populations, policies, 
practices, study design, and methods were evaluated. RESULTS: There has been 
a steady incidence of meningococcal disease in the U.S. since 1989 ranging from 
0.3–1.0/100,000 persons per year. Individuals under 1 year of age or between 15 
and 24 are generally at a higher risk of infection. High density living arrangements 
are a major risk factor for meningococcal infection. Worldwide, there is signiﬁ cant
variation in the incidence and management of meningococcal disease. The highest
incidence of meningitis is found in the “Meningitis Belt” of Africa with serotype A
responsible for 66% of disease. In Europe, the incidence of meningitis varies widely
from country to country ranging from 2.5/100,000 in Switzerland to 10.2/100,000 in
Greece. In general, countries react to outbreaks of meningococcal infection with tar-
geted vaccination programs. There is a high price associated with the use of conjugate
vaccines. In a probabilistic model of disease burden an adolescent catch-up vaccination 
program in the U.S. would cost society $127,000 per life year saved and $223,000 
per case averted. Outside the U.S. the cost per life year saved varied substantially by 
country and by study due to varying costs and modeling techniques. CONCLUSIONS:
Many nations in the developing world do not implement prevention strategies until 
an epidemic of meningococcal infection has inﬂ icted a substantial burden of disease, 
triggering aid organizations to support a catch-up vaccination campaign in response 
to an outbreak. Variations in health resources between countries signiﬁ cantly affect 
cost comparisons between countries.
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OBJECTIVES: The objective of the study was to explore variation in costs of ARTs
between low- and middle-income countries, lines of therapy, and drug regimens over 
time. METHODS: A search of database of WHO, Global Price Reporting Mechanism
(GPRM), Pubmed and relevant grey literature from 2004–2008 was undertaken. Two 
reviewers selected all descriptive or interventional studies involving cost associated 
with ART therapy in low- or middle-income countries (as deﬁ ned by World Bank cri-
teria) and compared it. RESULTS: Approximately 3,000,000 people are currently 
receiving ART in low-and middle-income countries. However, global coverage of ART 
is still limited, reaching 31% of the 9.7 million people in need at the end of 2007. In
2007, the weighted median price of the four most widely used combinations in ﬁ rst-
line treatment was US$188/person/year. The median price paid for ﬁ rst-line treatment 
in low-income countries in 2007 ranged from US$92/person/year for the ﬁ xed dose 
combination (FDC) of stavudine  lamivudine  nevirapine to US$294 for the FDC 
of zidovudine  lamivudine  efavirenz, whereas this price ranged from US$91 to 
US$357 for respective FDC’s for middle-income countries. The median cost of a
regimen of didanosine  abacavir  ritonavir-boosted lopinavir, the most commonly 
used second-line regimen was US$ 1214 in low-income countries and US$ 3306 in 
middle income countries. In low and middle-income countries, the prices of most
ﬁ rst-line treatments decreased by 30–64% from 2004 to 2007 whereas, the average
prices paid for second-line regimens remained high. CONCLUSIONS: Cost associated 
with ART is comparatively lower in low-income countries as compared to middle-
income countries for ﬁ rst-line as well as second-line treatment regimens. Costs of most
ﬁ rst-line treatments have decreased over time but coverage of ART still remains low 
in these countries.
